Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …

Individual variability in drug response (IVDR) can be a major cause of adverse drug
reactions (ADRs) and prolonged therapy, resulting in a substantial health and economic …

Recent advances in the genetics of metabolic dysfunction-associated steatotic liver disease
(MASLD) are gradually revealing the mechanisms underlying the heterogeneity of the …

Obesity is a complex and heterogeneous condition that leads to various metabolic
complications, including type 2 diabetes. Unfortunately, for some, treatment options to date …

The association of an individual's genetic makeup with their response to drugs is referred to
as pharmacogenomics. By understanding the relationship between genetic variants and …

Background Data to support individualised choice of optimal glucose-lowering therapy are
scarce for people with type 2 diabetes. We aimed to establish whether routinely available …